JRCT ID: jRCT2080225186
Registered date:11/05/2020
Basic Information
Recruitment status | recruiting |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 17/08/2020 |
Target sample size | 400 |
Countries of recruitment | Japan,Asia except Japan,North America,Europe,Oceania |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Selpercatinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Vandetanib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 12age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | Eli Lilly Japan K.K. |
---|---|
Secondary Sponsor | - |
Source(s) of Monetary Support | - |
Secondary ID(s) | NCT04211337,JapicCTI-205282 |